Hmmm Really? (7.11.2025)
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
Systemic sclerosis have more adverse pregnancy outcomes. Swedish Medical Birth Register study pre- & post SSc Dx (94 vs 978) finds incr risk post SSc for preeclampsia (RR 3.8), preterm birth (3.3), & caesarean (2.5). No incr of maternal or neonatal death, nor stillbirth https://t.co/9PWREN62r0
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic
Read Article
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N
Dr. John Cush @RheumNow( View Tweet )
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Links:
Dr. John Cush @RheumNow( View Tweet )
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR
Read Article
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was
Read Article
#CAR-T in active #scleroderma #diffuse
open label
@sclerodermaUM presented improvement in
#nailfold #capillary patterns
Suggesting #vascular recovery
Hope is for lungs, skin and survival to improve but
These are ▶️
Early days ?risk
OP0338
#EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk
Janet Pope @Janetbirdope( View Tweet )
Management and prognosis of RP by @Lupusreference
1. Pts with mild disease respond to GCs
2. NSAIDs/colchicine good alternatives
3. Most common biologics used: TNFi and IL6i
4. Consider CYP in life threatening dz/ICU pts
5. Dynamic CT assess tracheal collapse.
6. PET-CT can ≠ https://t.co/PNUecMZvkT
Links:
Adela Castro @AdelaCastro222( View Tweet )
Is #PDE5i protective in development of
#SSc #ILD?
Maybe
444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u
#immunesuppressive use maybe or not
🤷♀️channeling bias
Reduction in new #ILD in #scleroderma
PDE5i ✅
Immunesuppression ?
@RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV
Links:
Janet Pope @Janetbirdope( View Tweet )
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Links:
Janet Pope @Janetbirdope( View Tweet )
#digital #ulcers in #scleroderma🎯
Retrospective #iloprost vs #selexipag
👇
BIG advantage of oral #prostacyclin receptor #agonist vs iloprost
healing faster
⬇️ulcers
Selexipag used in iloprost failures; ⬇️IV access
WOW! RCT needed #OP035
#EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd
Links:
Janet Pope @Janetbirdope( View Tweet )
Predictors and Outcomes in Systemic Sclerosis
EurekAlert!
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
Read Article
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic
Read Article
🔬 Proud to present our poster at #EULAR2025!
📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study
KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc
📍F.136 https://t.co/woTMnTkRKY
Cristiana Sieiro Santos @cristianasieiro( View Tweet )
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM
Links:
Dr. Dinesh Khanna @sclerodermaUM( View Tweet )
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/pFBKjXqwfr
Dr. John Cush @RheumNow( View Tweet )
Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic sclerosis. Microcurrent Rx given for 45-60 min over 1-2d; w/ average improvement of 40% in hand function & Raynauds improvement ~18% p .016)- RCT needed!! https://t.co/4OUeODuj8Q
Dr. John Cush @RheumNow( View Tweet )
MTX Fails Knee OA (6.6.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
Systematic review of JAK inhibitor use in systemic sclerosis - 18 articles/87 SSc pts (80%F; ages 13–78 yrs). JAKi (83% tofa) mostly used for ILD & Skin Dz (45%) or GI+Skin Dz (39%). 87.5% improved, w/ 6% relapsed. Adverse events in 50% (20% infx). We need RCTs! This could be a https://t.co/VXFuHGpDjB
Dr. John Cush @RheumNow( View Tweet )
🔺CTD-ILD radiological signs to look out for 👀
#CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus
By @IlliasulK https://t.co/hHupTz0bCy
Dr Gurdeep S Dulay @gurdeep_dulay( View Tweet )
Diagnosing Neuropsychiatric SLE (5.23.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.
Read Article
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/Oi91niMn5M
Dr. John Cush @RheumNow( View Tweet )
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush @RheumNow( View Tweet )
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
